How we forecast tomorrow's haemovigilance

Erica M Wood; Barbee I Whitaker; Mary Townsend; Shruthi Narayan

doi:10.1016/j.tracli.2024.03.001

How we forecast tomorrow's haemovigilance

Transfus Clin Biol. 2024 May;31(2):114-118. doi: 10.1016/j.tracli.2024.03.001. Epub 2024 Mar 7.

Authors

Erica M Wood¹, Barbee I Whitaker², Mary Townsend³, Shruthi Narayan⁴

Affiliations

¹ School of Public Health and Preventive Medicine, Monash University, 553 St Kilda Road, Melbourne, Victoria 3004, Australia; Department of Clinical Haematology, Monash Health, Clayton Road, Clayton, Victoria 3168, Australia. Electronic address: erica.wood@monash.edu.
² Office of Biostatistics and Pharmacovigilance, Center for Biologics Evaluation and Research, Food and Drug Administration, Center for Biologics Evaluation and Research, 10903 New Hampshire Avenue, White Oak-71, Silver Spring, MD 20993, USA. Electronic address: Barbee.Whitaker@fda.hhs.gov.
³ Vitalant, 9503 E Via de Ventura, Scottsdale, AZ 85259, USA. Electronic address: mtownsend@vitalant.org.
⁴ Serious Hazards of Transfusion (SHOT), NHS Blood and Transplant, Manchester Blood Centre, Manchester M13 9LL, United Kingdom. Electronic address: Shruthi.Narayan@nhsbt.nhs.uk.

PMID: 38460837
DOI: 10.1016/j.tracli.2024.03.001

Abstract

The field of haemovigilance continues to develop, building on more than forty years of international experience. This review considers the current scope and activities of haemovigilance around the world and explores aspects of preparation for the advent of new blood products and alternative therapies to transfusion; new tools for data acquisition (including patient- and donor-reported outcomes, and data from 'wearables') and the analysis and communication of haemovigilance results.

Keywords: Adverse reactions; Blood transfusion; Haemovigilance; Patient safety.

Publication types

Review

MeSH terms

Blood Banks
Blood Donors
Blood Safety* / methods
Blood Transfusion*
Forecasting
Humans